EUCTR2007-002846-38-GB进行中（未招募）1 期
A multicenter, open-label, randomized, phase II/III study to evaluate the safety and efficacy of combretastatin a-4 phosphate in combination with paclitaxel and carboplatin in comparison with paclitaxel and carboplatin against anaplastic thyroid carcinoma - N/A
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Anaplastic thyroid carcinoma histologically or cytologically confirmed pathology, having been refractory to or progressed during or after therapy,. or relapsed within 6 months following initial combined modality therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Tumors confined to the thyroid or an uncontrolled active infection or clinically evident brain metastasis
研究者
相似试验
进行中（未招募）
1 期
A randomized, open-label, multi-center, phase II/III study on treatment with ABR-217620 combined with IFN-a vs. IFN-a alone in patients with advanced renal cell carcinoma. Protocol Version 1 dated 2006-10-06. Protocol Version 2 including Protocol Amendment 1 dated 2007-05-10. Protocol Version 3 including Protocol Amendment 2 dated 2007-11-07. Protocol Version 4 including Protocol Amendment 3 dated 2008-05-29.Renal Cell CarcinomaMedDRA version: 9.1Level: LLTClassification code 10038413Term: Renal cell carcinoma stage IIIMedDRA version: 9.1Level: LLTClassification code 10038414Term: Renal cell carcinoma stage IVEUCTR2006-004956-19-GBActive Biotech Research AB524
进行中（未招募）
不适用
A phase II/III study on treatment with ABR-217620 combined with IFN-a vs. IFN-a alone in patients with advanced renal cell carcinomaRenal Cell CarcinomaMedDRA version: 16.1Level: LLTClassification code 10038395Term: Renal carcinomaSystem Organ Class: 100000004864EUCTR2006-004956-19-BGActive Biotech AB524
进行中（未招募）
1 期
An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after first-line oxaliplatin - containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancerMedDRA version: 17.0Level: HLTClassification code 10008442Term: ChemotherapiesSystem Organ Class: 100000004865MedDRA version: 17.0Level: LLTClassification code 10069759Term: KRAS mutationSystem Organ Class: 100000004867colorectal cancerEUCTR2014-002417-36-ITFondazione IRCCS Istituto Nazionale dei Tumori82
进行中（未招募）
1 期
An open-label, randomized, multicenter, phase II, comparative, exploratory study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to Positon Emission Tomography (PET) value modification in patients with early stage HER2 positive breast cancer - AVATAXHERearly stage HER2 positive breast cancerMedDRA version: 12.0Level: PTClassification code 10057654Term: Breast cancer femaleEUCTR2009-013410-26-FRROCHE SAS156
进行中（未招募）
不适用
APG101 in glioblastomaGlioblastoma Multiforme (first or second progression)MedDRA version: 14.1Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-013421-42-DEApogenix GmbH83